Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 16Recruiting 9Unknown 6Withdrawn 3Terminated 2Not yet recruiting 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1Anorexia 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 184Nivolumab 180Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 111Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74Radiation 73atezolizumab 72venetoclax 68fludarabine 68Gemcitabine 68Standard of Care 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Olanzapine × Clear all
NCT04939090 2026-04-13

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Alliance for Clinical Trials in Oncology

Phase 3 Active not recruiting
227 enrolled
Other hematologic neoplasm

Anorexia, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡